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Patients with chronic fatigue syndrome
performed worse than controls in a controlled
repeated exercise study despite a normal
oxidative phosphorylation capacity
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Abstract
Background: The aim of this study was to investigate the possibility that a decreased mitochondrial ATP synthesis
causes muscular and mental fatigue and plays a role in the pathophysiology of the chronic fatigue syndrome (CFS/ME).
Methods: Female patients (n = 15) and controls (n = 15) performed a cardiopulmonary exercise test (CPET) by
cycling at a continuously increased work rate till maximal exertion. The CPET was repeated 24 h later. Before the
tests, blood was taken for the isolation of peripheral blood mononuclear cells (PBMC), which were processed in a
special way to preserve their oxidative phosphorylation, which was tested later in the presence of ADP and
phosphate in permeabilized cells with glutamate, malate and malonate plus or minus the complex I inhibitor
rotenone, and succinate with rotenone plus or minus the complex II inhibitor malonate in order to measure the
ATP production via Complex I and II, respectively. Plasma CK was determined as a surrogate measure of a
decreased oxidative phosphorylation in muscle, since the previous finding that in a group of patients with external
ophthalmoplegia the oxygen consumption by isolated muscle mitochondria correlated negatively with plasma
creatine kinase, 24 h after exercise.
Results: At both exercise tests the patients reached the anaerobic threshold and the maximal exercise at a much
lower oxygen consumption than the controls and this worsened in the second test. This implies an increase of
lactate, the product of anaerobic glycolysis, and a decrease of the mitochondrial ATP production in the patients. In
the past this was also found in patients with defects in the mitochondrial oxidative phosphorylation. However the
oxidative phosphorylation in PBMC was similar in CFS/ME patients and controls. The plasma creatine kinase levels
before and 24 h after exercise were low in patients and controls, suggesting normality of the muscular
mitochondrial oxidative phosphorylation.
Conclusion: The decrease in mitochondrial ATP synthesis in the CFS/ME patients is not caused by a defect in the
enzyme complexes catalyzing oxidative phosphorylation, but in another factor.
Trial registration: Clinical trials registration number: NL16031.040.07.
Background
Chronic fatigue syndrome/myalgic encephalopathy (CFS/
ME) as a syndrome was defined in consensus meetings
by Fukuda et al [1]. Fatigue was the major criterion in the
definition. It was described as suddenly occurring, not
explained, not caused by exercise, insufficiently relieved
by rest and causing a major reduction in physical capa-
city. The additional symptoms of the syndrome were
headache, pain in muscles and joints, unrefreshing sleep,
postexertional malaise, sore throat, painful lymph glands
and insufficient concentration. The combination of fati-
gue and four or more of the additional symptoms lasting
at least for 6 months, sufficed for the diagnosis of CFS/
ME. The main exclusion criterion for CFS/ME, was the
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presence of a disease that is generally accepted as an
actual cause of fatigue.
Several groups of investigators assume that a defective
oxidative phosphorylation and subsequent free radical
production and oxidative stress play an important role in
the pathophysiology of CFS/ME [2-11]. A well accepted
way to test ATP synthesis under increased work rate is
the cardiopulmonary exercise test (CPET) [12-16]. The
ATP synthesis is measured indirectly by testing for oxy-
gen uptake (V’O2) as a measure for oxygen consumption
(Q’O2) in an exercise protocol. Q’O2 can be restricted
when mitochondria are insufficiently active, or by a
restricted supply line of oxygen that consists of the lungs,
both ventilation and perfusion, the heart pump, the
blood vessels and the hemoglobin concentration in
the blood. Modern equipment and algorisms suggested
the exclusion of these latter causes of an inadequate
Q’O2, and supported the likelihood of inactivity of the
mitochondrial oxidative phosphorylation. This was also
suggested by the finding of a decreased anaerobic thresh-
old in the CFS/ME patients, which is determined by
CPET. The anaerobic threshold is the rate of oxygen con-
sumption, when the work rate is reached at which blood
lactic acid starts to accumulate, and is due to ATP synth-
esis from anaerobic glycolysis in muscles. In patients
with defects in the oxidative phosphorylation, the anaero-
bic threshold is also reached at a lower oxygen consump-
tion than in controls [17,18].
In this study we compared the CPET [19] with a
direct assay of the oxidative phosphorylation in periph-
eral mononuclear cells (PBMC), attempting to prove an
abnormality of this process in the patients. After 24 h
these tests were repeated.
Methods
Patients who visited the CFS/ME Clinic Amsterdam and
healthy sedentary controls were invited for the study. All
patients fulfilled the criteria of Fukuda et al [1] for CFS/
ME and reported the start of symptoms after an infec-
tious disease. Exclusion criteria were according to
Fukuda et al [1]. Contra indications for the CPET were
mainly cardiac diseases, hypertension, or the inability to
perform the exercise as in arthrosis of the knee. Medica-
tion was discontinued 2 weeks before the first test. All
subjects performed a CPET on a cycle ergometer (Excali-
bur, Lode, Groningen, The Netherlands) according to
our protocol: 3 min without activity, 3 min of unloaded
pedaling, followed by pedaling against increasing resis-
tance until exhaustion (RAMP protocol) and ended by
3 min pedaling with low resistance. The rate of work rate
increase was estimated from history, physical examina-
tion, gender, weight and height. The participants
performed symptom limited exercise tests as described
by Wassermann et al. [13]. Verbal encouragement to
perform maximally was used during the last phase of
incremental exercise. Exhaustion of the leg muscles was
the limiting symptom in all participants. The V’E, V’O2,
V’CO2 and oxygen saturation were continuously mea-
sured (Metasoft). The ECG was continuously recorded
and blood pressure was measured every 2 min. The
CPET was repeated after 24 h. The Respiratory Exchange
Rate (RER) was used for validation of the repeated CPET.
The exercise ECG of the subjects was analyzed (by
FCV). The anaerobic threshold was determined by the
V-slope method.
The participants completed questionnaires among
others (not shown) about additional symptoms of
CFS/ME (Centers for Disease Control and Prevention
Symptoms Inventory - Dutch Language Version (CDC
Symptom Inventory-DLV)) [20]. The criterion for fati-
gue was that at least 4 CFS/ME symptoms must be
≥7.5 [20].
All subjects were seen and an ECG was approved by
the internist (RMK).
The results of the tests were not available to the parti-
cipants or the investigators until after the last test was
performed by the participant.
Before entry into the study, the nature of the study
was explained to the participants and written consent
was obtained. The STEG independent ethics committee
approved the study. The trial was conducted in accor-
dance with the Declaration of Helsinki (1996 revision)
and under the principals of good clinical practice, as
laid out in the International Conference on Harmoniza-
tion document Good Clinical Practice Consolidated
Guideline.
ATP synthesis assay of PBMC
PBMC were isolated from 20 mL of blood obtained
before each CEPT and anti-coagulated with 0.18%
EDTA as described in detail elsewhere [21,22]. For
cryostorage in liquid nitrogen, PBMC were suspended at
1 × 107 cells/mL phosphate-buffered saline, pH 7.4, con-
taining 2 mM EDTA, 10% newborn calf serum and 10%
dimethyl sulfoxide. To study mitochondrial function,
PBMC were thawed and ATP production via reduction
of complex I or II was determined exactly as described
[22] except that the cell concentration was decreased to
only 5 × 104 cells per mL incubation medium. A small
sample was used to determine citrate synthase (CS)
activity according to Srere [23] and protein concentra-
tion by the Bio-Rad DC protein assay (Bio-Rad Labora-
tories) with bovine serum albumine as a standard. The
ATP synthesis rate was expressed as nmol ATP synthe-
sized per 30 min per U citrate synthase (CS) or per mg
protein.
Plasma creatine kinase (CK) is usually considered a
marker of non-specific muscle damage. In the plasma
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the activity of CK was measured, as a surrogate measure
of a lowered oxidative phosphorylation in skeletal mus-
cle. The rationale of this came from early work by
Driessen-Kletter et al. [24]. In a group of seven patients
with chronic external ophthalmoplegia a high negative
correlation of (R = -0.988; P = 0.0002) was found
between plasma CK 24 h after exercise, and the activity
of oxidative phosphorylation via reduction of complex I.
Plasma CK was tested by the Clinical Chemistry Labora-
tory (AKC) of Erasmus MC.
Statistical analysis
Statistical analyses were conducted using the Statistical
Package for the Social Sciences (17.0 for Windows,
Chicago, Ill, US). Kolmogorov-Smirnov tests for normal-
ity showed that the data were normally distributed. The
results were expressed as the mean ± standard deviation
(SD). Differences between groups were tested with mul-
tivariate or repeated measures Analysis of Variance
(ANOVA) where appropriate; correlations were tested
with Pearson’s correlation test.
Results
Patients
Inclusion of patients for the study started in May 2007
and the last CPET was in December 2007. Analysis of
the blood samples ended in March 2009. At screening 8
of the 23 patients fulfilled exclusion criteria for the
study. In the remaining patients, the results of the male
participants were significantly different from females.
The low number of male patients prevented separate
statistical analysis, therefore only the data of the 15
female participants were reported in this study, together
with 15 female healthy controls. Demographic data are
presented in Table 1 including the scores for the CDC
Symptom Inventory-DLV.
CPET1 and CPET2
The V’O2 max in CPET1 and CPET2 in the control
group were closely related (R = 0.994; P < 0.001).
Table 2 summarizes the results of CPET1 and CPET2.
At rest the Forced Vital Capacity, the Forced Expiratory
Volume (in the first second), the heart rate, oxygen con-
sumption and CO2 production were not different
between the patient and control group. At the anaerobic
threshold the two groups differed for the work rate.
(58.6 ± 24.2 W in patients, versus 82.9 ± 29.1 W; P =
0.019, 95% CI: -44.3; -4.3), oxygen uptake (12.8 ± 3.0
mL/kg versus 16.7 ± 4.0 mL/kg; P = 0.006, 95% CI:
-6.52; -1.22) and the ventilatory equivalent for CO2
(29.3 ± 2.3 versus 26.9 ± 1.5 in controls; P = 0.002, 95%
CI: 0.94; 3.86). At maximal work rate, similar differences
were seen: work rate (132 ± 30 W versus 188 ± 46 W;
P = 0.001, 95% CI: -85.5; -27.7), oxygen pulse (9.19 ±
2.18 mL/beat versus 12.43 ± 5.25; P = 0.036, 95% CI:
-6.25; -0.23) and oxygen uptake (22.3 ± 5.7 mL/kg ver-
sus 31.2 ± 7.0; P = 0.001, 95% CI: -13.71; -4.16). The
results of the second test showed the same differences
between the patients and controls (Table 2). The work
rate, oxygen pulse and oxygen uptake at the anaerobic
threshold and at maximal work rate in the first and sec-
ond test were closely correlated (paired t-test, P <
0.001). The oxygen pulse at rest in the first test corre-
lated with oxygen uptake at maximal work rate in the
first test (R = 0.63; P < 0.001) and in the second test
(R = 0.63; P < 0.001). The results of the CPET1 and
CPET2 showed significant correlations of all measures
in the 2 tests (Pearson’s test, P < 0.001).
The differences between the CPET2 and CPET1 are
shown in table 3. The FVC, the FEV1 and the results of
resting heart rate, oxygen consumption and CO2 pro-
duction did not change in the patient and control
group. At the anaerobic threshold the group of patients
performed worse and the controls improved. The work
rate was 4.40 ± 9.66 W less in the patient group and
7.67 ± 19.50 W higher in the control group (P = 0.002,
95% CI: -23.6; -0.55). Such differences were also found
for the oxygen pulse (-0.67 ± 0.93 mL/beat versus 0.25
± 1.09 mL/beat; P = 0.014, 95% CI: -1.68; -0.16) and
oxygen uptake (-0.87 ± 1.07 mL/kg versus 1.07 ± 2.63
mL/kg; P = 0.001, 95% CI: -3.61; -0.26). Similar changes
were found at maximal work rate: The work rate was
6.33 ± 11.5 W less in the patient group and 11.1 ± 18.3
W higher in the control group (P < 0.001, 95% CI:
-28.8; -5.99). And the changes in the oxygen uptake
were likewise (-1.33 ± 1.68 mL/kg versus 0.73 ± 1.39
mL/kg; P < 0.001, 95% CI: -3.22; -0.92). The improve-
ment in the performance of the controls is likely due to
the effect of training. In the group of patients the per-
formance is the result of a similar training effect which
is counteracted by the effect of the postexertional
malaise.
ATP synthesis in PBMC
The results are summarized in table 4. The cells were
isolated before the exercise tests. The amount of the
mitochondria of PBMC was estimated by the assay of
citrate synthase, and the activity was not different
Table 1 Age, body mass index and CDC Symptom score
in female patients and controls&
Patients n = 15 Controls n = 15
Age (y) 35.5 ± 11.9 35.6 ± 14.0
Body mass index (kg/m2) 23.1 ± 5.4 22.7 ± 4.3
CDC Symptom score 59.5 ± 13.1 5.0 ± 4.5*
&Data are presented as mean ± SD.
*.Statistically significant difference between patients and controls at P < 0.01.
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between the four groups (patients and controls at
CEPT1 and 2).
The ATP synthesis assayed via the reduction of com-
plex I, expressed on basis of protein were similar in the
groups, and also when the ATP synthesis rate was
expressed on basis of citrate synthase. The same was
found for ATP synthesis via complex II.
In the present study, plasma CK was low and not
increased before and 24 h after exercise in the patient
group, and not different from the control group, suggest-
ing no muscle damage and no major intrinsic abnormal-
ities of muscular oxidative phosphorylation in CFS/ME
patients.
Discussion
At rest the cardiopulmonary exercise test 1 and 2
showed no difference between patients and controls.
Increasing work rate made the differences obvious. The
lower V’O2 at the anaerobic threshold indicated that the
difference in V’O2 at maximal work rate was not due to
a reduced willingness to perform in the CFS/ME group.
The FEV1 and the FVC were not different, but the
higher ventilatory equivalent for CO2 at the anaerobic
threshold indicated the possibility of a ventilation-
perfusion mismatch in the patient group. The reproduci-
bility of CPET was high, relatively poor performers at the
Table 2 CPET1 and CPET2 in CSF/ME patients versus controls&
CPET1 CPET2
Patients n = 15 Controls n = 15 Patients n = 15 Controls n = 15
FVC (L) 3.70 ± 0.73 3.71 ± 0.77 3.71 ± 0.73 3.76 ± 0.72
FEV 1 (L) 2.95 ± 0.61 2.98 ± 0.55 2.94 ± 0.46 3.05 ± 0.53
Rest
Heart rate (beats/min) 86.5 ± 10.6 80.7 ± 8.6 87.9 ± 11.2 80.9 ± 8.8
O2 pulse (mL/beat) 4.43 ± 0.72 4.73 ± 0.86 4.26 ± 0.76 4.73 ± 0.88
V’O2/kg [mL/(min.kg)] 5.93 ± 1.28 6.27 ± 0.80 5.87 ± 1.30 6.20 ± 0.56
Anaerobic Threshold
WR (Watt) 58.6 ± 24.2 82.9 ± 29.1* 54.5 ± 20.9 92.9 ± 31.1**
Heart rate (beats/min) 110 ± 14 111 ± 10 112 ± 13 118 ± 10#
O2 pulse (mL/beat) 7.69 ± 1.50 9.19 ± 2.42 7.01 ± 1.74 # 9.48 ± 2.69**
V’O2/kg [mL/(min.kg)] 12.8 ± 3.0 16.7 ± 4.0** 11.9 ± 2.9 18.0 ± 4.6**#
V’E/V’CO2 29.2 ± 2.3 26.9 ± 1.5** 29.1 ± 3.7 25.7 ± 2.0**#
Maximal exercise
WR (Watt) 132 ± 30 188 ± 46** 125 ± 35 196 ± 51** ##
Heart rate (beats/min) 158 ± 20 167 ± 8 155 ± 21 168 ± 8*
O2 pulse (mL/beat) 9.19 ± 2.18 12.43 ± 5.25* 8.82 ± 2.20. 11.70 ± 3.01**
V’O2/kg [mL/(min.kg)] 22.3 ± 5.7 31.2 ± 7.0** 20.9 ± 5.5 ## 31.9 ± 7.4**#
&Data are presented as mean ± SD.
Differences evaluated by multivariate or repeated measures ANOVA:
*: P < 0.05; ** P < 0.01 between patients and controls.
#: P < 0.05; ## P < 0.01 between CPET1 and CPET2.
Table 3 Difference between CPET2 and CPET1 in patients
and controls&
CPET2 minus CPET1
Patients n = 15 Controls n = 15
FVC (L) 0.01 ± 0.21 0.05 ± 0.18
FEV 1 (L) 0.00 ± 0.32 0.07 ± 0.17
Rest
Heart rate (beats/min) 1.33 ± 6.29 0.20 ± 6.24
O2 pulse (mL/beat) -0.17 ± 0.41 0.01 ± 0.47
V’O2/kg [mL/(min.kg)] -0.07 ± 0.70 -0.07 ± 0.80
Anaerobic Threshold
WR (Watt) -4.40 ± 9.66 7.67 ± 19.50*
Heart rate (beats/min) 2.60 ± 7.79 4.60 ± 10.16
O2 pulse (ml/beat) -0.67 ± 0.93 0.25 ± 1.09*
V’O2/kg [mL/(min.kg)] -0.87 ± 1.77 1.07 ± 2.63*
V’E/V’CO2 -0.21 ± 2.05 -13.8 ± 50.1
Maximal exercise
WR (Watt) -6.3 ± 11.5 11.1 ± 18.3**
Heart rate (beats/min) -3.3 ± 8.6 11.9 ± 41.6
O2 pulse (mL/beat) -0.37 ± 0.70 -4.6 ± 15.0
V’O2/kg [mL/(min.kg)] -1.33 ± 1.68 0.73 ± 1.39**
&Data are presented as mean ± SD.
Differences between patients and controls evaluated by multivariate ANOVA:
*: P < 0.05; ** P < 0.01.
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first test ranked low in the second test too. There were sig-
nificant differences between the patients and controls.
Based on the oxygen uptake test, the patients not only per-
formed worse than controls in the first test, but the recov-
ery after 24 h was not completed in this group as well. This
indicates an impaired recovery [25], as expressed in the cri-
terion “postexertional malaise” of the CDC Symptom score.
A limited mitochondrial ATP synthesis was the
working hypothesis for this investigation. This is prob-
ably not true, as the energy production can be limited
by other mechanisms as well. The exercise tests with
increased work load suggested the possibility that the
mitochondrial ATP synthesis was decreased, because
the anaerobic threshold was reached. Then the mito-
chondria were not longer able to produce sufficient
ATP to sustain the exercise, and the anaerobic glycoly-
sis in muscle had to produce the extra ATP needed,
which is reflected by the lactate production. This is
also the case in patients with defects in the oxidative
phosphorylation. Peripheral blood mononuclear cells
are commonly used to assess the gene expression in
CFS/ME [26-34], and the expressions of various genes
involved in mitochondrial protein synthesis, energy
metabolism, and in free radical metabolism were found
to be changed. The results of the present study do not
support a physiological effect of these changes, and
demonstrated that the oxidative phosphorylation in
PCMB of CFS/ME patients is fully normal. And it is
likely that also their muscle mitochondria are normal,
since 24 h after strenuous exercise CK did not leak to
the blood, as is the case in patients with defective oxi-
dative phosphorylation.
A recent publication [6] claimed to have found a defec-
tive oxidative phosphorylation in neutrophils of CFS/ME
patients, but the flux through this process had not been
measured. These investigators performed a so called
“ATP profile” test, and determined ATP under five
different conditions, and the sum of these was found to
be abnormal in 70 of 71 patients. One of us (WS) was
involved in an investigation that clearly showed that neu-
trophils do not catalyze oxidative phosphorylation and
the remaining complexes of the respiratory chain main-
tain the mitochondrial membrane potential [35]. Their
mitochondria are only active in apoptosis [36].
In line with the present work, Mathew et al [37] dis-
covered by proton magnetic resonance spectroscopy
imaging that ventricular cerebrospinal lactate was 3.5-
fold increased in CFS/ME patients. McCully and Natel-
son [38] demonstrated by combined near-infrared
spectroscopy and 31P magnetic resonance spectroscopy
that during exercise the oxygen delivery to skeletal
muscle was delayed. Neary et al [39] established by
near-infrared spectrometry that the oxygenation of the
prefrontal brain lobe was decreased in exercising
patient to 67% of that in controls, confirming the
results of a study by Streeten and Bell [40] and Hur-
witz et al [41] and in line with a decreased blood
volume in CFS patients.
Conclusions
The decrease in mitochondrial ATP production at
increasing work rate, detected by the CPET tests in the
present well-characterized though small group of CFS/
ME patients, is a secondary phenomenon. This was
shown by the normality of the oxidative phosphorylation
in peripheral blood mononuclear cells. The chain of
mechanisms that couple (external) pulmonary to (inter-
nal) cellular respiration showed no abnormal differences
in this study between CFS patients and healthy controls
at the pulmonary, cardiac and circulatory level. Two pos-
sible explanations for the insufficient energy production
in CFS remained: a lower transport capacity of oxygen as
in anemia or a mitochondrial insufficiency. We showed
that the mitochondrial ATP production shows no defect.
Table 4 Citrate synthase activity, and complex I- and II-dependent oxidative phosphorylation in PBMC and CK in
plasma of CFS patients and controls before CPET1 and CPET2&
CPET1 CPET2
Patients n = 15 Controls n = 15 Patients n = 15 Controls n = 15
Citrate synthase (CS) U/g protein 135 ± 61 132 ± 17 128 ± 20 154 ± 51
ATP synthesis via Complex I nmol/(0.5 h. mg protein) 7.1 ± 3.1 7.8 ± 2.8 6.7 ± 4.8 9.5 ± 5.7
ATP synthesis via Complex I nmol/(0.5 h. U CS) 54 ± 19 58 ± 21 54 ± 34 61 ± 26
ATP synthesis via Complex II nmol/(0.5 h. mg protein) 7.8 ± 5.0 8.2 ± 2.8 6.8 ± 4.9 8.9 ± 5.3
ATP synthesis via Complex II nmol/(0.5 h. U CS) 58 ± 22 60 ± 26 54 ± 36 58 ± 27
CK in plasma U/L 70 ± 25 83 ± 35 64 ± 22 96 ± 63
&Data are presented as mean ± SD.
There were no statistically significant differences between patients and controls at CPET1 or 2 (according to multivariate ANOVA), or between CEPT1 and 2 for
patients or for controls (according to repeated measures ANOVA).
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Then the conclusion must be that the transport capacity
of oxygen is limited in CFS patients.
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